Tyche Industries Ltd (532384)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Tyche Industries' revenue was ₹9.1 Cr (-28.4% year on year, -43.8% on the previous quarter), and net profit ₹-0.0 Cr (against a profit a year earlier); the operating margin was -18.6%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹9.1 | -28.4% | -43.8% |
| Operating profit | ₹-1.7 | to loss | loss widened |
| Net profit | ₹-0.0 | to loss | to loss |
| EPS (₹) | -0.04 | to loss | to loss |
| Operating margin | -18.6% | — | — |
📢 Recent Corporate Announcements
Tyche Industries Limited has confirmed the dispatch and payment of its final dividend for the financial year 2025-26. The company declared a dividend of 35% on face value, amounting to ₹3.50 per equity share. Payments began on October 13, 2026, for eligible shareholders registered as of the record date, September 23, 2026.
- Declared dividend of 35% on equity face value (₹3.50 per share)
- Payment of dividend commenced on October 13, 2026
- Record date for dividend entitlement was September 23, 2026
- Relates to dividend declared for financial year 2025-26
Tyche Industries reported a weak performance for the quarter ended June 30, 2026, with revenue from operations falling 28.4% YoY to ₹9.09 Cr. The company swung to a net loss of ₹0.04 Cr from a profit of ₹2.43 Cr in the previous year's corresponding quarter. Critically, the statutory auditor issued a qualified opinion, stating that revenue was overstated by ₹1.60 Cr and net profit by ₹0.48 Cr due to non-compliance with Ind-AS 115 revenue recognition norms. Exports remain the primary revenue driver, contributing ₹6.77 Cr or 74.4% of total revenue.
- Revenue from operations declined to ₹9.09 Cr from ₹12.70 Cr in the year-ago quarter.
- Reported a net loss of ₹4.17 Lakhs compared to a net profit of ₹2.43 Cr in June 2025.
- Statutory auditor qualified the results, noting revenue is overstated by ₹160.43 Lakhs due to premature recognition.
- Export sales contributed ₹6.77 Cr, representing 74.4% of the total revenue from operations.
- Total expenses of ₹11.41 Cr exceeded the total operating income of ₹9.09 Cr.
Tyche Industries reported a weak Q1 FY27, swinging to a net loss of ₹0.04 Cr from a profit of ₹2.43 Cr in the year-ago period. Revenue from operations declined 28.3% YoY to ₹9.10 Cr, significantly below the TTM average. The results are further impacted by a statutory auditor qualification regarding premature revenue recognition, which led to an overstatement of revenue by ₹1.60 Cr and profit by ₹0.49 Cr for the quarter. Exports remain the dominant revenue driver, contributing 74.5% of the total operating income.
- Revenue from operations fell 28.3% YoY to ₹9.10 Cr from ₹12.70 Cr in June 2025.
- Reported a Net Loss of ₹0.04 Cr compared to a Net Profit of ₹2.43 Cr in the same quarter last year.
- Statutory auditors qualified the report, noting revenue was overstated by ₹1.60 Cr due to incorrect timing of income recognition.
- Export sales contributed ₹6.78 Cr, while domestic sales stood at ₹2.32 Cr.
- Total expenses of ₹11.41 Cr exceeded the operating revenue of ₹9.10 Cr, leading to an operating loss.
Tyche Industries has scheduled a board meeting for August 11, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. This follows a fiscal year (FY26) where revenue declined 18% to ₹53.63 Cr and operating margins compressed sharply to 4.18% from 17.23% in the previous year. Investors will be monitoring if the company can recover from the operating losses seen in two of the last four quarters. The trading window for insiders has been closed since July 1, 2026.
- Board meeting scheduled for August 11, 2026, at 4:30 PM to approve Q1 results.
- Trading window for designated persons closed from July 1, 2026, until 48 hours post-announcement.
- Company reported a TTM revenue of ₹54 Cr against a market capitalization of ₹126 Cr.
- FY26 operating profit margin stood at 4.18%, a significant drop from 17.23% in FY25.
- Current reactor capacity remains at 153 KL across 6 production blocks.
Financial Performance
Revenue Growth by Segment
Overall revenue declined by 21.19% YoY, falling from INR 54.07 Cr in FY2016 to INR 42.61 Cr in FY2017, primarily due to a reduction in orders in hand. A longer-term decline is noted from INR 63.87 Cr in FY2015.
Geographic Revenue Split
Not disclosed in available documents; however, the company operates a manufacturing unit in Kakinada, Andhra Pradesh, and a registered office in Hyderabad.
Profitability Margins
Net profit margin improved from 4.57% in FY2016 to 7.23% in FY2017. RoCE increased from 5.19% to 11.36% over the same period, indicating improved capital efficiency despite lower revenues.
EBITDA Margin
OPBDITA margin expanded significantly from 5.42% in FY2016 to 14.07% in FY2017, reflecting a 159.6% improvement in core operating profitability percentage.
Capital Expenditure
The company maintains 6 production blocks with a total reactor capacity of 153 KL. Specific planned CapEx for FY2026 is not disclosed, though INR 0.30 Cr was transferred to General Reserves in FY2025.
Credit Rating & Borrowing
The company previously held an [ICRA]BB+ (Stable) long-term and [ICRA]A4+ short-term rating for INR 12.50 Cr in bank facilities. These ratings were withdrawn in July 2018 at the company's request following a no-due certificate from its banker. The company reported no outstanding loans or one-time settlements during FY2025.
Operational Drivers
Raw Materials
Fine chemicals and chemical intermediates used for API manufacturing (representing the primary cost base for pharmaceutical production).
Capacity Expansion
Current installed reactor capacity is 153 KL across 6 production blocks. Future expansion timelines are not specified in the provided reports.
Raw Material Costs
Not disclosed as a specific percentage of revenue; however, the company identifies manufacturing and supply as a major risk factor requiring robust mitigation.
Manufacturing Efficiency
The company operates 6 production blocks; specific capacity utilization percentages for FY2025 are not disclosed.
Strategic Growth
Growth Strategy
The company is focusing on a sustainable business model within the Pharma sector, leveraging its 153 KL reactor capacity and R&D investments to capitalize on positive market scenarios for APIs and intermediates.
Products & Services
Active Pharmaceutical Ingredients (APIs) and Intermediates for anti-retroviral, anti-depression, anti-arthritic, anti-diarrheal, and anti-psychotic therapeutic segments.
Brand Portfolio
Tyche Industries Limited.
Market Expansion
The company targets the global pharma sector, though specific new regional targets for FY2026 are not detailed.
Market Share & Ranking
Not disclosed in available documents; recognized as Forbes 'Asia’s 200 Best under A Billion' in 2020.
External Factors
Industry Trends
The pharmaceutical sector is viewed as having a 'good' future market scenario. The industry is shifting toward more robust regulatory compliance and sustainable manufacturing practices.
Competitive Landscape
Operates in the competitive API and fine chemicals market; specific competitor names are not listed.
Competitive Moat
Competitive advantage is derived from its multi-block manufacturing infrastructure (153 KL capacity) and R&D focus, evidenced by international recognition (Forbes 2020). Sustainability is managed through a 'Going Concern' accounting basis and robust internal financial controls.
Macro Economic Sensitivity
Highly sensitive to pharmaceutical industry cycles and global healthcare spending trends.
Consumer Behavior
Demand is driven by global therapeutic needs for chronic conditions like depression, arthritis, and HIV (anti-retrovirals).
Regulatory & Governance
Industry Regulations
Complies with the Companies Act 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, and SEBI (Prohibition of Insider Trading) Regulations 2015. Manufacturing is subject to pharmaceutical regulatory standards.
Environmental Compliance
The company maintains a Corporate Social Responsibility (CSR) Committee and follows applicable environmental standards for chemical manufacturing, though specific INR spend is not detailed.
Taxation Policy Impact
Not thoroughly reviewed in secretarial audits; subject to statutory financial audit and professional review.
Legal Contingencies
No applications or proceedings are pending under the Insolvency and Bankruptcy Code, 2016. No reported frauds or material legal defaults were noted by auditors for FY2025.
Risk Analysis
Key Uncertainties
Manufacturing and supply chain disruptions, regulatory changes, and currency fluctuations are identified as the primary uncertainties that could impact margins by an unspecified percentage.
Geographic Concentration Risk
Manufacturing is concentrated in a single location in Kakinada, Andhra Pradesh.
Technology Obsolescence Risk
Information Technology is identified as a major risk; the company conducts in-house training to maintain technical and functional capabilities.
Credit & Counterparty Risk
Historical credit reports noted high debtors; however, internal financial controls are reported as operating effectively in FY2025 to ensure reliable financial records.
